Andrew T. Chan

发表

Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry.

Zina-Mary Manjaly, C. Kamm, J. Kuhle, 2022, Multiple sclerosis and related disorders.

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

C. Pozzilli, P. Vermersch, H. Hartung, 2022, Frontiers in Immunology.

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis

F. Barkhof, L. Leocani, X. Montalban, 2022, Neurology: Neuroimmunology & Neuroinflammation.

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

X. Montalban, P. Vermersch, A. Traboulsee, 2021, Multiple sclerosis.

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets

F. Barkhof, X. Montalban, P. Vermersch, 2022, Neurology: Neuroimmunology & Neuroinflammation.

Speci ﬁ c Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged E ﬃ cacy of Cladribine Tablets A MAGNIFY-MS Substudy

F. Barkhof, L. Leocani, X. Montalban, 2022 .

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

D. Conen, K. Blennow, C. Granziera, 2022, The Lancet Neurology.

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies

C. Pozzilli, P. Vermersch, B. Sharrack, 2021, Neurology and Therapy.

Factors associated with material deprivation in persons with multiple sclerosis in Switzerland: Cross-sectional data from the Swiss Multiple Sclerosis Registry.

Zina-Mary Manjaly, C. Kamm, P. Calabrese, 2022, Multiple sclerosis and related disorders.